Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratoy failure in patients suffering from COVID-19.
Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities Biophytis publishes its financial results for the first half of 2024 and provides an update on the company’s key achievements. Stanislas Veillet, CEO of Biophytis, commented: “We are particularly pleased with the progress made in the first half of 2024. The launch…
During the recent European Respiratory Society (ERS) conference held in Vienna, Prof. Capucine Morelot-Panzini, Head of Pneumonology at Pitié-Salpêtrière Hospital and Professor at Sorbonne University, presented the positive results of the COVA phase 2/3 trial on 20-hydroxyecdysone (BIO101) for the treatment of hospitalized severe COVID-19 patients. Her presentation highlighted a statistically significant reduction in the…
Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Biophytis announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These…
Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Biophytis announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). The primary objective of the study is to measure…
Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Biophytis presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26,…
RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Biophytis announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with…
Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million Biophytis announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and…
Biophytis extends its contract with Atlas to secure financing for its business activities Biophytis announces the extension of its bond financing agreement with Atlas, a specialized investment fund based in New York (USA), in order to secure financing for its business activities, in particular the launch of its clinical programs OBA in obesity and MYODA…
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Seqens, an integrated global player in solutions and ingredients for the pharmaceutical and speciality markets, offering a broad portfolio of active ingredients, pharmaceutical intermediates and speciality products, has produced the first GMP-compliant batch of BIO101 (20-hydroxyecdysone) at its plant in…
Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Biophytis announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) regarding its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). Fullscreen Mode
Combined General Meeting of June 24, 2024 Biophytis will hold its Combined General Meeting (CGM) on June 24, 2024 at 2pm at Sorbonne Université – Amphi Herpin – 4 Place Jussieu, 75005 Paris. The notice of meeting, including the agenda, the draft resolutions and the terms and conditions of attendance, was published in Bulletin des…
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and…
Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Our lead drug candidate, BIO101 (20-hydroxyecdysone), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.
BIOPHYTIS ON THE STOCK MARKET
Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015.
ISIN FR001400OLP5
Ticker: ALBPS
Type of listing: continuous
Total number of shares at 31/10/2024: 6,851,806
1 ADR = 10 shares
Number of voting rights at 31/10/2024: 6,875,736
Eligible for PEA and PEA-PME equity saving plans
Click here for live stock price